These 2 ASX shares could be good opportunities

Credit Corp and FINEOS could be ASX share ideas.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There are a group of ASX shares that may be options to look at because of their current valuations, according to brokers.

Businesses that are well-liked by multiple brokers could be an opportunity staring investors in the face. But it could also mean that all of those brokers are wrong at the same time.

Multiple analysts have said the below two businesses are ones that could be opportunities:

A stopwatch ticking close to the 12 where the words on the face say 'Time to Buy'.

Image source: Getty Images

Credit Corp Group Limited (ASX: CCP)

Credit Corp is a large debt collector that's operating in both Australia and the USA. It also has a lending division in Australia and New Zealand.

The business is currently rated as a buy by at least three different brokers, including Morgans which has a price target on the business of $33.75.

In FY21, Credit Corp saw a near-record investment outlay driven by the purchased debt ledger (PDL) acquisition from Collection House Limited (ASX: CLH) and a return to lending, despite a COVID-induced temporary reduction in PDL supply.

The ASX share said that FY22 started off well, with a record July contracted purchasing pipeline. The month on month charge-off volumes were also starting to grow.

Overall, the FY21 profit was driven by the US performance. Total revenue fell 1%, but ANZ debt buying profit increased 11% to $54.1 million and US debt buying profit more than doubled to $17.7 million. That helped total profit grow 11% to $88.1 million.

In FY22, Credit Corp is expecting to generate net profit after tax of between $85 million to $95 million, with PDL acquisitions of between $200 million to $240 million.

Based on Morgans' numbers, the Credit Corp share price is valued at 22x FY22's estimated earnings.

FINEOS Corp Holdings PLC (ASX: FCL)

FINEOS describes itself as a global company providing software to the employee benefits, life, accident and health industry. It offers clients purpose-built products. One of its offerings is called AdminSuite which takes care of new business, billing, claims, absence and policy administration, which enables "improved operational efficiency, increased effectiveness and excellent customer care."

It's currently rated as a buy by at least three brokers, including Citi, which has a price target on the ASX tech share of $5.22. After a recent capital raising, Citi thinks the company is well funded to put some of the capital to work in its current business, as well as trying to find other potential businesses to buy.

In FY21, FINEOS generated €108.3 million of revenue, up 23.3%. It also saw 23% of gross profit growth to €72 million.

In FY22, the ASX share is expecting revenue to be in the range of €125 million to €130 million, with subscription revenue anticipated to grow by around 30%. It's expecting to be successful with its pipeline of cross-selling and up-selling opportunities with existing clients and new wins.

At the time of the capital raising, FINEOS CEO Michael Kelly said:

Following a strong FY21 result, FINEOS continues to execute on its strategic priorities and invest in further product development and recent acquisition integrations. Our growth expectations for FY22 are underpinned by a pipeline of cross-sell and up-sell opportunities with existing clients in addition to new name opportunities. The equity raising ensures FINEOS has the balance sheet strength and financial flexibility to aggressively pursue those opportunities and accelerate growth.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended FINEOS Corporation Holdings plc. The Motley Fool Australia has recommended FINEOS Corporation Holdings plc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

A man looking at his laptop and thinking.
Broker Notes

Buy, hold, sell: What this leading broker is saying about Lynas shares

Is it bullish or bearish? Let's find out.

Read more »

share buyers, investors, happy investors
Broker Notes

Bell Potter's top ASX 200 holdings revealed

These are the top holdings in the broker's core portfolio.

Read more »

An athlete runs fast with a trail of yellow smoke billowing out behind him.
Broker Notes

Up 139% in a year, why this buy rated ASX All Ords rare earths stock could keep racing higher

A leading broker forecasts more outperformance to come from this surging ASX rare earths stock.

Read more »

Miner with thumbs up at a mine.
Gold

2 ASX gold miners to buy for solid share price gains, according to Barrenjoey

The Africa-focused companies are deeply undervalued after recent sell-offs, the broker says.

Read more »

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A happy family of four on holidays stand on a jetty and cheer.
Broker Notes

Down 40% in 2026, should you buy the big dip in Life360 shares?

A leading analyst offers his outlook for Life360 shares.

Read more »

Buy and sell on yellow paper with pins on them and several share price lines.
Broker Notes

Sell alert! Why this expert is calling time on Nuix and Brainchip shares

A leading analyst forecasts more pain to come for Brainchip and Nuix shares. But why?

Read more »

a man lies on his back on grass with his eyes shut and a contented look on his face as though he is dreaming
Broker Notes

With global populations ageing, are ResMed shares a good buy today?

A leading expert delivers his verdict on the outlook for ResMed shares.

Read more »